American Society of Gene and Cell Therapy (ASGCT) Symposium: Extending Genetically Modified T cells to CD19-Negative Hematologic Malignancies

American Society of Gene and Cell Therapy (ASGCT) Symposium: Extending Genetically Modified T cells to CD19-Negative Hematologic Malignancies

Chairs:
Catherine M. Bollard, Children’s Natl. Med. Ctr., George Washington Univ.
Saar Gill, Univ. of Pennsylvania

Speakers:

• Catherine M. Bollard, Children’s Natl. Med. Ctr., George Washington Univ., Overcoming TGF-β as an immune evasion strategy
• Terry J. Fry, NCI, NIH, Potential for improving durability of CAR-induced remissions
• Saar Gill, Univ. of Pennsylvania, CAR T cells for myeloid malignancies
• Maksim Mamonkin, Baylor Col. of Med., Targeting T cell malignancies with CAR T cells